Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Patients and data tracking

- PMLiVE

Agile strategy or strategy for ‘agile’?

By Maxine Smith and Melissa Dagless

- PMLiVE

WHO unveils AI-powered digital health worker, Florence 2.0

The chatbot builds on its previous version, which was used to tackle COVID-19 misinformation

- PMLiVE

Brainomix set to collaborate with NCIMI to assess AI-powered tech in lung cancer care

The partnership will compare automated evaluation versus observations of medical specialists

- PMLiVE

Alnylam’s RNAi therapeutic expanded by FDA in advanced primary hyperoxaluria type 1

A phase 3 trial showed Oxlumo treatment resulted in substantial reductions in plasma oxalate

- PMLiVE

New study links omega-3 intake in midlife to reduced dementia risk

Over 2,000 people who did not have dementia or stroke took part in the study

Infographic: Therapy Watch Psoriasis

Our PsO infographic offers an introduction to the real-world patient insights collected by our Therapy Watch PsO study.

Inizio

- PMLiVE

Porterhouse Insights celebrates its 5th anniversary

Porterhouse Medical Group is celebrating the 5th anniversary of Porterhouse Insights, its global research, insights and evidence consultancy.

Porterhouse Medical Group

Thought Leaders in Medical Affairs: Key Trends & Challenges Shaping the Future of the Medical Affairs Role

How can Medical Affairs divisions bring greater value to their organizations and practitioners every day?

Medscape Medical Affairs

- PMLiVE

Future-proofing pharma supply chains by improving inefficiencies in global health architecture

By Rich Quelch

- PMLiVE

Pfizer completes acquisition of Global Blood Therapeutics for $5.4bn

The deal includes a pipeline of sickle cell disease targeted treatments including Oxbryta

- PMLiVE

EMA accepts Santen’s application for glaucoma treatment STN1013001

The intraocular pressure lowering efficacy was demonstrated in a phase 3 trial

- PMLiVE

Eli Lilly granted fast track designation by FDA for obesity treatment

The company plans to initiate a rolling submission of a new drug application for tirzepatide this year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links